Cancer imaging agents for positron emission tomography: Beyond FDG

Current Medical Imaging Reviews

Volumn 3, Issue 3, 2007, Pages 178-185

  Paul, Asit K ^a   Abdel Nabi, Hani ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Cancer imaging; Imaging agent; Positron emission tomography

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; 1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; ACETIC ACID; ACETIC ACID C 11; ANTINEOPLASTIC AGENT; ARGINYLGLYCYLASPARTIC ACID; CARBON 11; CHOLINE; CHOLINE KINASE; COPPER 64; FLUORINE 18; FLUOROACETIC ACID F 18; FLUORODEOXYGLUCOSE F 18; FLUOROETHYLTYROSINE F 18; FLUOROMETHYLCHOLINE F 18; FLUOROTHYMIDINE F 18; GLUCOSE 6 PHOSPHATASE; GLUCOSE TRANSPORTER; HEXOKINASE; HYPOXIA INDUCIBLE FACTOR 1; IODINE 124; METHIONINE; METHIONINE C 11; THYMIDINE; THYMIDINE C 11; THYMIDINE KINASE 1; THYMIDINE PHOSPHORYLASE; TRACER; TYROSINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BRAIN CANCER; BREAST CANCER; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CYCLOTRON; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG CLEARANCE; DRUG EXCRETION; DRUG METABOLISM; DRUG RESPONSE; DRUG SYNTHESIS; DRUG UPTAKE; DRUG URINE LEVEL; ESOPHAGUS CANCER; HEAD AND NECK CANCER; HUMAN; LUNG NODULE; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; LYMPHOMA; MELANOMA; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; REVIEW; SENSITIVITY AND SPECIFICITY; THYROID CANCER; TREATMENT INDICATION; UTERINE CERVIX CANCER;

EID: 34547877245     PISSN: 15734056     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340507781386997     Document Type: Review

References (92)

1. Weber WA. Positron emission tomography as an imaging biomarker. J Clin Oncol 2006 10; 24: 3282-92.
2. Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology 2004; 231: 305-32.
3. Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME. A tabulated summary of the FDG PET literature. J Nucl Med 2001; 42: 1S-93S.
4. 18F-FDG in oncology. J Nucl Med Technol 2002; 30: 3-9.
5. Avril NE, Weber WA. Monitoring response to treatment in patients utilizing PET. Radiol Clin North Am 2005; 43: 189-204.
6. Saleem A, Charnley N, Price P. Clinical molecular imaging with positron emission tomography. Eur J Cancer 2006; 42: 1720-7
7. 11C]choline. J Nucl Med 1997; 38: 842-47.
8. DeGrado TR, Baldwin SW, Wang S, et al. Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET Tracers. J Nucl Med 2001; 42: 1805-14.
9. Warburg O. On the origin of cancer cells. Science 1956; 123: 309-314.
10. Pauwels EK, Ribeiro MJ, Stoot JH, McCready VR, Bourguignon M, Maziere B. FDG accumulation and tumor biology. Nuel Med Biol 1998; 25: 317-22.
11. 18F-FDG distribution with regional expression of glucose transporters and hexokinase-II in experimental tumor. J Nucl Med 2005; 46: 675-82.
12. Shreve PD, Grossman HB, Gross MD, Wahl RL. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18] fluoro-D-glucose. Radiology 1996; 199: 751-6.
13. Adams S, Baum R, Rink T, Schumm-Drager PM, Usadel KH, Hor G. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med 1998; 25: 79-83.
14. Heyneman LE, Patz EF. PET imaging in patients with bronchioloalveolar cell carcinoma. Lung Cancer 2002; 38: 261-6.
15. Trojan J, Schroeder O, Raedle J, et al. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma. Am J Gastroenterol 1999; 94: 3314-9.
16. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992; 33: 1972-80.
17. 18F-FDG uptake in human endothelial cells in vitro. J Nucl Med 2004; 45: 455-60.
18. Fischman AJ, Thornton AF, Frosch MP, Swearinger B, Gonzalez RG, Alpert NM.FDG hypermetabolism associated with inflammatory necrotic changes following radiation of meningionia. J Nucl Med 1997; 38: 1027-9.
19. Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using carbon-11-chohne. J Nucl Med 1998; 39: 990-5.
20. Kotzerke J, Prang J, Neumaier B, et al. Experience with carbon-II choline positron emission tomography in prostate carcinoma. Eur J Nucl Med 2000; 27: 1415-9.
21. 11C-choline positron emission tomography. Eur Urol 2002; 42: 18-23
22. 18F]fluorodeoxyglucose-positron emission tomography. J Urol 2003; 169: 1337-40.
23. 11C-choline positron emission tomography/computerized tomography for tumor localization of primary prostate cancer in comparison with 12-core biopsy. J Urol 2006; 176: 954-60;
24. 11C-choline PET/CT. J Nucl Med 2006; 47: 1249-54.
25. 11C-acetate PET imaging of prostate cancer. J Nucl Med 2002; 43: 181-6.
26. Kotzerke J, Volkmer BG, Neumaier B, Gschwend JE, Hautmann RE, Reske SN. Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancer. Eur J Nucl Med Mol Imag 2002; 29: 1380-4
27. Sandblom G, Sorensen J, Lundin N, Haggman M, Malmstrom PU. Positron emission tomography with C-11-acetate for tumor detection and localization in patients with prostate-specific antigen relapse after radical prostatectomy. Urology 2006; 67: 996-1000.
28. 11C-acetate PET imaging of prostate cancen detection of recurrent disease at PSA relapse. J Nucl Med 2003; 44: 549-55.
29. Shinoura N, Nishijima M, Hairs, T, et al. Brain tumors: detection with C-11 choline PET. Radiology 1997; 202: 497-503.
30. Ohtani T, Kurihara H, Ishiuchi S, et al. Brain tumour imaging with carbon-11 choline: comparison with FDG PET and gadolinium-enhanced MR imaging. Eur J Nucl Med 200 1; 28: 1664-70.
31. 11C-acetate. Eur J Nucl Med Mol Imag 2006; 33: 420-7.
32. Ogawa T, Shishido F, Kanno I, et al. Cerebral glioma: evaluation with methionine PET. Radiology 1993; 186: 45-53.
33. Kaschten B, Stevenaert A, Sadzot B, et al. Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. J Nucl Med 1998; 39: 778-85.
34. 11C-methionine for PET-guided stereotactic brain biopsy of gliomas. J Nucl Med 2004; 45: 1293-8.
35. 11C) methionine positron emission tomography for target delineationin resected high-grade gliomas before radiotherapy. Int J Radiat Oncol Biol Phys 2005; 63: 64-74.
36. Nuutinen J, Sonninen P, Lehikoinen P, et al. Radiotherapy treatment planning and long-term follow-up with [(11)C] methionine PET in patients with low-grade astrocytoma. Int J Radiat Oncol Biol Phys 2000; 48: 43-52.
37. 11C]methionine PET, histopathology, and survival in primary brain tumors and recurrence. AJNR Am J Neuroradiol 2006; 27: 1432-7.
38. 18F-FDG PET. Eur J Nucl Med Mol Imag 2005; 32: 52-9.
39. 11C-methionine PET to monitor the effects of temozolomide chemotherapy in malignant gliomas. Eur J Nucl Med Mol Imag 2006; 33: 516-24.
40. 125I Seeds. Stereotact Fund Neurosurg 1997; 69: 129-35.
41. Wurker M, Herholz K, Voges J, et al. Glucose consumption and methionine uptake in low-grade gliomas after iodine-125 brachytherapy. Eur J Nucl Med 1996; 23: 583-6.
42. Bustany P, Chatel M, Derlon JM, et al. Brain tumor protein synthesis and histological grades: a study by positron emission tomography (PET) with C-11 -L-Methionine. J Neurooncol 1986; 3: 397-404.
43. 11C-methionine PET for differential diagnosis of low-grade gliomas. Neurology 1998; 50: 1316-22.
44. Been LB, Elsinga PH, de Vries J, et al. Positron emission tomography in patients with breast cancer using (18)F-3′-deoxy-3′-fluoro-1-thymidine ((18)F-FLT) - a pilot study. Eur J Surg Oncol 2006; 32: 39-43.
45. Pio BS, Park CK, Pietras R, et al. Usefulness of 3′-[F-18]fluoro-3′-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol Imaging Biol 2006; 8: 36-42.
46. Buck AK, Bommer M, Stilgenbauer S, et al. Molecular imaging of proliferation in malignant lymphoma. Cancer Res 2006; 66: 11055-61.
47. 18F-FDG. J Nucl. Med 2005; 46: 945-52.
48. 18F]3′-deoxy-3′-fluorothymidine PET for the diagnosis and grading of brain tumors. Eur J Nucl Med Mol Imag 2005; 32: 653-9.
49. 18F-fluorodeoxyglucose-positron emission tomography. Chest 2006; 129: 393-401.
50. 18F-3′-fluoro-3′-deoxy-L-thymidine useful for the staging and restaging of nonsmall cell lung cancer? J Nucl Med 2004; 45: 1677-82.
51. Rajendran JG, Schwartz DL, O'Sullivan J, et al. Tumor hypoxia imaging with, [F-18] fluoromisonidazole positron emission tomography in head and neck cancer. Clin Cancer Res 2006; 12: 5435-41.
52. 18F]FMISO correlates with radiation therapy outcome in headand-neck cancer patients. Radiother Oncol 2006; 80: 151-6.
53. Nordsmark M, Bentzen SM, Rudat V, et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 2005; 77: 18-24.
54. 2-polarography in metastatic head and neck cancer. Eur J Nucl Med Mol Imaging 2006; 33: 1426-31.
55. Hicks RJ, Rischin D, Fisher R, Binns D, Scott AM, Peters LJ. Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent. Eur J Nucl Med Mol Imag 2005; 32: 1384-91.
56. Koh WJ, Bergman KS, Rasey JS, et al. Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidaiole positron emission tomography. Int J Radiat Oncol Biol Phys 1995; 33: 391-8.
57. 18F-FDG PET. J Nucl Med 2006; 47:1921-1926.
58. 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med 2005; 46: 253-60.
59. 18F-FDG PET, and immunohistochemical studies. J Nucl Med 2006; 47: 410-8.
60. Duyn JH, Alger JR, Di Chiro G. Increased choline signal coinciding with malignant degeneration of cerebral gliomas: a serial proton magnetic resonance spectroscopy imaging astudy. J Neurosurg 1997; 87: 516-24.
61. Ackerstaff E, Pflug BR, Nelson JB, Bhujwalla ZM. Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostate epithelial cells. Cancer Res 2001; 61: 3599-603.
62. Podo F. Tumor phospholipid metabolism. NMR Biomed 1999; 12: 413-39
63. 18F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol 2002; 168: 273-80.
64. Yoshimoto M, Waki A, Yonekura Y, et al. Characterization of acetate metabolism in tumor cells in relation to cell proliferation: acetate metabolism in tumor cells. Nucl Med Biol 2001; 28: 117-22.
65. Shreve P, Chiao PC, Humes HD, Schwaiger M, Gross MD. Carbon-11-acetate PET imaging in renal disease. J Nucl Med 1995; 36: 1595-601.
66. 11C-acetate PET imaging in hepatocellular carcinoma and other liver masses. J Nucl Med 2003; 44: 213-21.
67. 18-fluoroacetate using PET/CT. Eur J Nucl Med Mol Imag 2004; 31: 797.
68. Seltzer MA, Jahan SA, Sparks R, et al. Radiation dose estimates in humans for (11)C-acetate whole-body PET. J Nucl Med 2004; 45: 1233-6.
69. 11C] acetate in normal prostate and benign prostatic hyperplasia: comparison with prostate cancer. Eur J Nucl Med Mol Imag 2002; 29: 1492-5.
70. Busch H, Davis JR, Honig GR, Anderson DC, Nair PV, Nyhan WL. The uptake of a variety of amino acids into nuclear proteins of tumors and other tissues. Cancer Res 1959; 19: 1030-9.
71. Saier MH Jr, Daniels GA, Boerner P, Lin J. Neutral amino acid transport systems in animal cells: potential targets of oncogene action and regulators of cellular growth. J Memb Biol 1988; 104: 1-20.
72. Kubota K, Matsuzawa T, Ito M, et al. Lung tumor imaging by positron emission tomography using C-11 L-methionine. J Nucl Med 1985; 26: 37-42.
73. Kubota R, Kubota K, Yamada S, et al. Methionine uptake by tumor tissue: a microautoradiographic comparison with FDG. J Nucl Med 1995; 36: 484-92.
74. Floeth FW, Stummer W. The value of metabolic imaging in diagnosis and resection of cerebral gliomas. Nat Clin Pract Neurol 2005; 1:62-3.
75. Jager PL, Vaalburg W, Pruim J, de Vries EG, Langen KJ, Piers DA. Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med 2001; 42: 432-45.
76. Shields AF, Mankoff D, Graham MM, et al. Analysis of 2-carbon-11-thymidine blood metabolites in PET imaging. J Nucl Med 1996; 37: 290-6.
77. Grierson JR, Shields AF. Radiosynthesis of 3′-deoxy-3′-[(18)F] fluorothymidine: [(18)F]FLT for imaging of cellular proliferation in vivo. Nucl Med Biol 2000; 27: 143-56.
78. Shields AF, Grierson JR, Dohmen BM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 1998; 4: 1334-6.
79. Sherley JE, Kelly TJ. Regulation of human thymidine kinase during the cell cycle. J Biol Chem 1988; 263: 8350-8.
80. Rasey JS, Grierson JR, Wiens LW, Kolb PD, Schwartz JL. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med 2002; 43: 1210-7.
81. Vesselle H, Grierson J, Muzi M, et al. In vivo validation of 3′deoxy-3′-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: correlation of [(18)F]FLT) uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin Cancer Res 2002; 8:3315-23.
82. 18F-FDG PET in esophageal cancer. J Nucl Med 2005; 46: 400-4.
83. Francis DL, Freeman A, Visvikis D, et al. In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomography. Gut 2003; 52:1602-6.
84. Apisarnthanarax S, Alauddin MM, Mourtada F, et al. Early detection of chemoradioresponse in esophageal carcinoma by 3′-deoxy-3′-3H-fluorothymidine using preclinical tumor models. Clin Cancer Res 2006; 12: 4590-7.
85. Sugiyama M, Sakahara H, Sato K, et al. Evaluation of 3′-deoxy-3′-18F-fluorothymidine for monitoring tumor response to radiotherapy and photodynamic therapy in mice. J Nucl Med 2004; 45: 1754-8.
86. Stone HB, Brown JM, Phillips TL, Sutherland RM. Oxygen in human tumors: correlations between methods of measurement and response to therapy. Summary of a workshop held November 1920, 1992, at the National Cancer Institute, Bethesda, Maryland. Radiat Res 1993; 136: 422-34.
87. Koh WJ, Rasey JS, Evans ML, et al. Imaging of hypoxia in human tumors with [F-18] fluoromisonidazole. Int J Radiat Oncol Biol Phys 1992; 22: 199-212.
88. Rajendran JG, Wilson DC, Conrad EU, et al. [(18)F]FMISO and [(18)F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression. Eur J Nucl Med Mol Imag 2003; 30: 695-704.
89. 18F]FETNIM: a potential marker for PET. J Nucl Med 2001; 42: 1397-404.
90. Yang DJ, Wallace S, Cherif A, Li C, Gretzer MB, Kim EE, Podoloff DA. Development of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia. Radiology 1995; 194: 795-800.
91. Gatenby RA, Kessler HB, Rosenblum JS, et al. Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys 1988; 14: 831-8.
92. Teicher BA. Hypoxia and drug resistance. Cancer Metastasis Rev 1994; 13: 139-68.